Condensed Consolidated Statement of Changes in Stockholder Deficit - USD ($)
|
Common Stock [Member] |
Additional Paid-In-Capital [Member] |
Deferred Compensation [Member] |
Accumulated Deficit [Member] |
Total |
Balance at Dec. 31, 2016 |
$ 85,069
|
$ 51,963,269
|
|
$ (55,933,862)
|
$ (3,885,524)
|
Balance, shares at Dec. 31, 2016 |
85,068,709
|
|
|
|
|
Common stock grants to independent directors |
$ 793
|
149,207
|
|
|
150,000
|
Common stock grants to independent directors, shares |
793,025
|
|
|
|
|
Common stock issuance to institutional investor |
$ 568
|
59,432
|
|
|
60,000
|
Common stock issuance to institutional investor, shares |
567,644
|
|
|
|
|
Restricted stock issuances |
$ 34,108
|
4,044,327
|
|
|
4,078,435
|
Restricted stock issuances, shares |
34,107,883
|
|
|
|
|
Restricted stock issuance to a broker for fees |
$ 559
|
44,141
|
|
|
44,700
|
Restricted stock issuance to a broker for fees, shares |
558,750
|
|
|
|
|
Stock option exercises - cashless |
$ 645
|
(645)
|
|
|
|
Stock option exercises - cashless, shares |
645,288
|
|
|
|
770,000
|
Warrant exercise |
$ 733
|
39,267
|
|
|
$ 40,000
|
Warrant exercise, shares |
733,217
|
|
|
|
|
Deferred compensation |
$ 200
|
40,300
|
(10,125)
|
|
30,375
|
Deferred compensation, shares |
200,000
|
|
|
|
|
Stock based compensation - options |
|
61,771
|
|
|
61,771
|
Net loss |
|
|
|
(1,985,234)
|
(1,985,234)
|
Balance at Dec. 31, 2017 |
$ 122,675
|
56,401,069
|
(10,125)
|
(57,919,096)
|
(1,405,477)
|
Balance, shares at Dec. 31, 2017 |
122,674,516
|
|
|
|
|
Common stock grants to independent directors |
$ 907
|
199,093
|
|
|
200,000
|
Common stock grants to independent directors, shares |
906,774
|
|
|
|
|
Stock option exercises - cashless |
$ 157
|
(157)
|
|
|
|
Stock option exercises - cashless, shares |
156,997
|
|
|
|
|
Deferred compensation |
|
|
10,125
|
|
10,125
|
Deferred compensation, shares |
|
|
|
|
|
Cardax 2018 Warrant Exchange Offering, net |
$ 9,600
|
1,234,437
|
|
|
1,244,037
|
Cardax 2018 Warrant Exchange Offering, net, shares |
9,600,286
|
|
|
|
|
Stock based compensation - options |
|
233,124
|
|
|
233,124
|
Net loss |
|
|
|
(3,076,873)
|
(3,076,873)
|
Balance at Sep. 30, 2018 |
$ 133,339
|
58,067,566
|
|
(60,995,969)
|
(2,795,064)
|
Balance, shares at Sep. 30, 2018 |
133,338,573
|
|
|
|
|
Balance at Dec. 31, 2017 |
$ 122,675
|
56,401,069
|
(10,125)
|
(57,919,096)
|
(1,405,477)
|
Balance, shares at Dec. 31, 2017 |
122,674,516
|
|
|
|
|
Common stock grants to independent directors |
$ 1,345
|
286,155
|
|
|
287,500
|
Common stock grants to independent directors, shares |
1,344,274
|
|
|
|
|
Stock option exercises - cashless |
$ 157
|
(157)
|
|
|
|
Stock option exercises - cashless, shares |
156,997
|
|
|
|
200,000
|
Deferred compensation |
|
|
10,125
|
|
$ 10,125
|
Deferred compensation, shares |
|
|
|
|
|
Cardax 2018 Warrant Exchange Offering, net |
$ 9,600
|
1,234,437
|
|
|
1,244,037
|
Cardax 2018 Warrant Exchange Offering, net, shares |
9,600,286
|
|
|
|
|
Stock based compensation - options |
|
330,146
|
|
|
330,146
|
Common stock grant to service providers |
$ 112
|
22,388
|
|
|
22,500
|
Common stock grant to service providers, shares |
112,500
|
|
|
|
|
Net loss |
|
|
|
(4,024,222)
|
(4,024,222)
|
Balance at Dec. 31, 2018 |
$ 133,889
|
58,274,038
|
|
(61,943,318)
|
(3,535,391)
|
Balance, shares at Dec. 31, 2018 |
133,888,573
|
|
|
|
|
Balance at Jun. 30, 2018 |
$ 123,301
|
56,653,005
|
|
(60,067,081)
|
(3,290,775)
|
Balance, shares at Jun. 30, 2018 |
123,300,787
|
|
|
|
|
Common stock grants to independent directors |
$ 438
|
87,062
|
|
|
87,500
|
Common stock grants to independent directors, shares |
437,500
|
|
|
|
|
Deferred compensation |
|
|
|
|
|
Deferred compensation, shares |
|
|
|
|
|
Cardax 2018 Warrant Exchange Offering, net |
$ 9,600
|
1,234,437
|
|
|
1,244,037
|
Cardax 2018 Warrant Exchange Offering, net, shares |
9,600,286
|
|
|
|
|
Stock based compensation - options |
|
93,062
|
|
|
93,062
|
Net loss |
|
|
|
(928,888)
|
(928,888)
|
Balance at Sep. 30, 2018 |
$ 133,339
|
58,067,566
|
|
(60,995,969)
|
(2,795,064)
|
Balance, shares at Sep. 30, 2018 |
133,338,573
|
|
|
|
|
Balance at Dec. 31, 2018 |
$ 133,889
|
58,274,038
|
|
(61,943,318)
|
(3,535,391)
|
Balance, shares at Dec. 31, 2018 |
133,888,573
|
|
|
|
|
Common stock grants to independent directors |
$ 1,627
|
260,873
|
|
|
262,500
|
Common stock grants to independent directors, shares |
1,627,191
|
|
|
|
|
Restricted stock issuances |
$ 1,633
|
243,367
|
|
|
$ 245,000
|
Restricted stock issuances, shares |
1,633,330
|
|
|
|
|
Stock option exercises - cashless, shares |
|
|
|
|
|
Stock based compensation - options |
|
257,875
|
|
|
$ 257,875
|
Common stock grant to service providers |
$ 113
|
14,287
|
|
|
14,400
|
Common stock grant to service providers, shares |
112,500
|
|
|
|
|
Issuance of warrants attached to a convertible note |
|
141,435
|
|
|
141,435
|
Net loss |
|
|
|
(3,650,740)
|
(3,650,740)
|
Balance at Sep. 30, 2019 |
$ 137,262
|
59,191,875
|
|
(65,594,058)
|
(6,264,921)
|
Balance, shares at Sep. 30, 2019 |
137,261,594
|
|
|
|
|
Balance at Jun. 30, 2019 |
$ 136,641
|
58,908,648
|
|
(64,160,432)
|
(5,115,143)
|
Balance, shares at Jun. 30, 2019 |
136,640,761
|
|
|
|
|
Common stock grants to independent directors |
$ 583
|
86,917
|
|
|
87,500
|
Common stock grants to independent directors, shares |
583,333
|
|
|
|
|
Stock based compensation - options |
|
84,875
|
|
|
84,875
|
Common stock grant to service providers |
$ 38
|
3,300
|
|
|
3,338
|
Common stock grant to service providers, shares |
37,500
|
|
|
|
|
Issuance of warrants attached to a convertible note |
|
108,135
|
|
|
108,135
|
Net loss |
|
|
|
(1,433,626)
|
(1,433,626)
|
Balance at Sep. 30, 2019 |
$ 137,262
|
$ 59,191,875
|
|
$ (65,594,058)
|
$ (6,264,921)
|
Balance, shares at Sep. 30, 2019 |
137,261,594
|
|
|
|
|